News | Remote Monitoring | February 19, 2019

Ochsner Health System Implementing New Cardiac Device Monitoring Platform

Louisiana-based health system will use Geneva Health Solutions’ cloud-based platform to monitor patient cardiac devices in five-state region

Ochsner Health System in Louisiana recently announced a new partnership with device data management and remote monitoring vendor Geneva Health Solutions (GHS) for implantable EP cardiac devices.

Ochsner Health System in Louisiana recently announced a new partnership with device data management and remote monitoring vendor Geneva Health Solutions (GHS) for implantable EP cardiac devices. 

February 19, 2019 — Ochsner Health System in Louisiana recently announced a new partnership with device data management and remote monitoring vendor Geneva Health Solutions (GHS) for implantable cardiac devices. This partnership marks the first time the GHS cloud-based technology platform and remote monitoring service for patients with cardiac implants will be utilized in the region, which includes Louisiana, Arkansas, Mississippi, Alabama and Georgia. The GHS system will drive full automated scheduling and reporting in collaboration with Ochsner’s established Epic electronic medical record (EMR).

Todd Mule, vice president, cardiology service line, Ochsner Health System, said, “Ochsner is committed to investing in patient-centric technology and are confident that partnering with Geneva Health Solutions will further enhance what we are able to offer our patient and coordinated care team through our electronic medical records platform, Epic. Ochsner’s investment in and enthusiasm for technology offers our patients enhanced coordination of care, convenience and better results.”

Millions of Americans have implanted cardiac devices. Patients with these devices — such as pacemakers, defibrillators and loop recorders — transmit critical cardiac data from their implanted device from the comfort of their homes to the provider via the cloud. These transmissions allow providers to monitor their patients proactively for both routine device follow-up and alerts regarding device issues or clinical events, like atrial fibrillation and other indicators of heart failure. The GHS patent-pending platform aggregates cardiac device data from all major device manufacturers’ remote monitoring portal, in-office checks and ER visits. The GHS remote monitoring service helps providers manage the incoming data in an outpatient setting.

For more information: www.genevahealthsolutions.com

Related Content

Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...
Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
AHA Statement Warns Hookah Smoking May Harm the Heart
News | Cardiac Diagnostics | March 08, 2019
Smoking tobacco in waterpipes, more commonly known as hookahs, results in inhaling toxic chemicals, often at levels...
Overlay Init